On the other hand, patients (n = 36) with PPARγ positive MM metastases who had been treated either with pro-anakoinotic metronomic low-dose chemotherapy (trofosfamide) alone or combined with COX-2/ PPARγ -targeting drugs, i.e., rofecoxib and pioglitazone, showed a significant advantage concerning progression-free survival (p = 0.044), but not overall survival (p = 0.179). Here, PTGS2 is linked to Miyoshi myopathy.